Fibromyalgia

None of them clear our grade B bar. Magnesium is grade C: a plausible mechanism around muscle and nerve excitability, but only small, underpowered trials. Vitamin D is grade C and only helps people who are genuinely deficient, correcting a real deficiency is the supportable action, not supplementing above normal levels. CoQ10 is grade C: several small positive trials, no large confirmatory trial. The honest verdict: cheap, low risk, worth discussing with your doctor, but do not expect much, and do not spend real money expecting a result. This carries no product recommendation.

Three drugs are FDA-approved specifically for fibromyalgia: pregabalin (2007), duloxetine (2008), and milnacipran (2009), grade B, resting on the approval basis plus randomized trials. Amitriptyline is guideline-recommended and widely used off-label, but it is not FDA-approved for fibromyalgia, and the 2015 Cochrane review (Moore et al.) found no first- or second-tier evidence for it and rated the supporting trials very low quality, so treat it as grade C and mixed, the same honest split this page already gives low-dose naltrexone. Non-drug: pacing, already the highest-value step on this page. Every drug named here is a conversation with your clinician, never a self-start.

Fibromyalgia is real, and it is not in your head. It is a real, recognized disorder of how the nervous system processes pain, not a psychiatric condition and not a diagnosis of exclusion. The best-supported mechanism is central sensitization: the brain and spinal cord amplify pain signals. This is measurable with quantitative sensory testing, which consistently finds people with fibromyalgia are more sensitive to standardized pressure and heat than controls, grade B, a well-replicated finding across many independent studies. Brain imaging adds supporting but less settled evidence: a systematic review of structural and functional MRI studies (Cagnie et al., Seminars in Arthritis and Rheumatism, 2014) found moderate evidence of reduced grey matter in pain-processing regions like the anterior cingulate cortex, grade C, real but heterogeneous across studies and not a diagnostic scan. A subset of patients also show small-fiber neuropathy on skin biopsy, roughly 40 to 50 percent in pooled estimates (Oaklander et al., Pain, 2013; meta-analysis PMID 30314675), grade C, a real physical finding in a meaningful minority but not present in everyone and not required for diagnosis. Institutionally, fibromyalgia is formally recognized by the American College of Rheumatology, has its own World Health Organization ICD-11 code (MG30.01, chronic widespread pain), and has dedicated management guidelines from EULAR (2017) and NICE (NG193, 2021). None of that adds up to a cure, and no scan or blood test can diagnose it today, but the pain is physiologically real and it has a name every major medical body recognizes.

The old 1990 American College of Rheumatology criteria (Wolfe et al., Arthritis and Rheumatism, 1990) required a doctor to press on 18 specific points and find tenderness in at least 11 of them. That exam was retired years ago. The current standard is the 2016 revision (Wolfe et al., Seminars in Arthritis and Rheumatism, 2016) of the 2010/2011 criteria, and it does not use tender-point pressing at all. It uses two scored scales: the Widespread Pain Index (WPI, 0 to 19, counting painful body areas) and the Symptom Severity Scale (SSS, 0 to 12, scoring fatigue, unrefreshing sleep, cognitive symptoms and other complaints). Criteria are met with WPI 7 or higher and SSS 5 or higher, or WPI 4 to 6 with SSS 9 or higher, plus generalized pain in at least 4 of 5 body regions, with symptoms present at a similar level for at least 3 months. One line matters most for a dismissive visit: the criteria state outright that a fibromyalgia diagnosis is valid irrespective of other diagnoses, and does not exclude the presence of other clinically important illness. It is not a last-resort label for when nothing else is found, and it can coexist with other conditions. A doctor is not applying the current standard if they are still pressing on 18 points or treating it as a diagnosis that only counts once everything else is ruled out. Meeting these numbers is not a diagnosis: only a clinician can diagnose fibromyalgia, using this criteria alongside your full clinical picture.

Bring the criteria, not just your symptoms: ask specifically whether your pain and symptom pattern meet the 2016 ACR criteria (WPI and SSS scored, generalized pain in at least 4 of 5 regions, present at a similar level for 3 or more months), and ask whether the outdated 18-point tender-point exam is being used instead. A reasonable workup rules out other explanations for widespread pain, commonly thyroid function, inflammatory markers (ESR and CRP), and vitamin D, not to disprove your pain but to check for a treatable overlapping condition, since a fibromyalgia diagnosis does not exclude having something else too. If a clinician will not apply a named, published diagnostic standard to a real symptom pattern, asking for a rheumatology referral or a second opinion is a reasonable next step, not an overreaction. This is informational only, not a diagnosis; only a clinician can diagnose fibromyalgia.